141 related articles for article (PubMed ID: 11881524)
1. Alefacept. Amevive, BG 9273, human LFA-3/Igg fusion protein, LFA 3, LFA 3 TIP LFA 3/CD2, LFA-3/Igg fusion protein, LFA3TIP, recombinant LFA-3/Igg1 human fusion protein, recombinantly engineered LFA-1/Igg1 human fusion protein.
Drugs R D; 2002; 3(1):21-4. PubMed ID: 11881524
[No Abstract] [Full Text] [Related]
2. Alefacept (Biogen).
Bashir SJ; Maibach HI
Curr Opin Investig Drugs; 2001 May; 2(5):631-4. PubMed ID: 11569937
[TBL] [Abstract][Full Text] [Related]
3. Alefacept for the treatment of psoriasis and other dermatologic diseases.
Strober BE; Menon K
Dermatol Ther; 2007; 20(4):270-6. PubMed ID: 17970892
[TBL] [Abstract][Full Text] [Related]
4. Alefacept for psoriasis and psoriatic arthritis.
Gottlieb AB
Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv58-60. PubMed ID: 16239390
[TBL] [Abstract][Full Text] [Related]
5. The use of alefacept in the treatment of psoriasis.
Wong VK; Lebwohl M
Skin Therapy Lett; 2003 Sep; 8(6):1-2, 7. PubMed ID: 14610613
[TBL] [Abstract][Full Text] [Related]
6. Changes in circulating lymphocyte subpopulations following administration of the leucocyte function-associated antigen-3 (LFA-3)/IgG1 fusion protein alefacept.
Larsen R; Ryder LP; Svejgaard A; Gniadecki R
Clin Exp Immunol; 2007 Jul; 149(1):23-30. PubMed ID: 17403057
[TBL] [Abstract][Full Text] [Related]
7. The effects of an immunomodulatory LFA3-IgG1 fusion protein on nonhuman primates.
Chisholm PL; Williams CA; Jones WE; Majeau GR; Oleson FB; Burrus-Fischer B; Meier W; Hochman PS
Ther Immunol; 1994 Aug; 1(4):205-16. PubMed ID: 7584496
[TBL] [Abstract][Full Text] [Related]
8. Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells.
da Silva AJ; Brickelmaier M; Majeau GR; Li Z; Su L; Hsu YM; Hochman PS
J Immunol; 2002 May; 168(9):4462-71. PubMed ID: 11970990
[TBL] [Abstract][Full Text] [Related]
9. Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival.
Kaplon RJ; Hochman PS; Michler RE; Kwiatkowski PA; Edwards NM; Berger CL; Xu H; Meier W; Wallner BP; Chisholm P; Marboe CC
Transplantation; 1996 Feb; 61(3):356-63. PubMed ID: 8610340
[TBL] [Abstract][Full Text] [Related]
10. Possibilities of using alefacept in the treatment of psoriasis.
Pietrzak A; Chodorowska G; Bartkowiak-Emeryk M; Pietrzak B; Urban J; Juszkiewicz-Borowiec M; Miturska R
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(2):311-3. PubMed ID: 15323211
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulation by LFA3TIP, an LFA-3/IgG1 fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers.
Meier W; Gill A; Rogge M; Dabora R; Majeau GR; Oleson FB; Jones WE; Frazier D; Miatkowski K; Hochman PS
Ther Immunol; 1995 Jun; 2(3):159-71. PubMed ID: 8885134
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration.
Vaishnaw AK; TenHoor CN
J Pharmacokinet Pharmacodyn; 2002 Dec; 29(5-6):415-26. PubMed ID: 12795239
[TBL] [Abstract][Full Text] [Related]
13. Alefacept therapy produces remission for patients with chronic plaque psoriasis.
Krueger GG; Ellis CN
Br J Dermatol; 2003 Apr; 148(4):784-8. PubMed ID: 12752139
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice.
Majeau GR; Meier W; Jimmo B; Kioussis D; Hochman PS
J Immunol; 1994 Mar; 152(6):2753-67. PubMed ID: 7511625
[TBL] [Abstract][Full Text] [Related]
15. Alefacept: where it stands today.
Chaarani J; Lebwohl M
Expert Opin Drug Metab Toxicol; 2010 Mar; 6(3):355-61. PubMed ID: 20163322
[TBL] [Abstract][Full Text] [Related]
16. Alefacept (Amevive) for treatment of psoriasis.
Med Lett Drugs Ther; 2003 Apr; 45(1154):31-2. PubMed ID: 12717339
[No Abstract] [Full Text] [Related]
17. Development and use of alefacept to treat psoriasis.
Krueger GG; Callis KP
J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S87-97. PubMed ID: 12894131
[TBL] [Abstract][Full Text] [Related]
18. Preface: real-world clinical experience with alefacept-the Amevive Wisdom Acquired from Real-World Evidence (AWARE) study.
Searles G; Bissonnette R; Landells I; Shear NH
J Cutan Med Surg; 2009 Dec; 13 Suppl 3():S107-12. PubMed ID: 20053322
[No Abstract] [Full Text] [Related]
19. Alefacept.
Frampton J; Wagstaff A
Am J Clin Dermatol; 2003; 4(4):277-86; discussion 287. PubMed ID: 12680805
[TBL] [Abstract][Full Text] [Related]
20. Alefacept, first biologic agent approved for treatment of psoriasis.
Piascik P
J Am Pharm Assoc (2003); 2003; 43(5):649-50. PubMed ID: 14626761
[No Abstract] [Full Text] [Related]
[Next] [New Search]
